Salarius Pharmaceuticals Statistics
Share Statistics
Salarius Pharmaceuticals has 1.44M shares outstanding. The number of shares has increased by -63.41% in one year.
| Shares Outstanding | 1.44M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 141.38% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.40M |
| Failed to Deliver (FTD) Shares | 4 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 65.04K, so 4.51% of the outstanding shares have been sold short.
| Short Interest | 65.04K |
| Short % of Shares Out | 4.51% |
| Short % of Float | 4.63% |
| Short Ratio (days to cover) | 0.08 |
Valuation Ratios
The PE ratio is -1353.46 and the forward PE ratio is -0.16.
| PE Ratio | -1353.46 |
| Forward PE | -0.16 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 3.21 |
| P/FCF Ratio | -1.32 |
| PEG Ratio | n/a |
Enterprise Valuation
Salarius Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 5.02, with a Debt / Equity ratio of 0.05.
| Current Ratio | 5.02 |
| Quick Ratio | 5.02 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 5.19 |
| Cash Flow / Debt | -44.35 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is -0.23%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | -0.23% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -6.27K |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -71.32% in the last 52 weeks. The beta is 0.93, so Salarius Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.93 |
| 52-Week Price Change | -71.32% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 2.69 |
| Relative Strength Index (RSI) | 48.43 |
| Average Volume (20 Days) | 327.57K |
Income Statement
In the last 12 months, Salarius Pharmaceuticals had revenue of $0 and earned -$12.54K in profits. Earnings per share was $0.
| Revenue | 0 |
| Gross Profit | -10.05K |
| Operating Income | -12.89K |
| Net Income | -12.54K |
| EBITDA | -2.84K |
| EBIT | - |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has $5.90M in cash and $289.64K in debt, giving a net cash position of $5.61M.
| Cash & Cash Equivalents | 5.90M |
| Total Debt | 289.64K |
| Net Cash | 5.61M |
| Retained Earnings | -76.35M |
| Total Assets | 3.86M |
| Working Capital | 3.33M |
Cash Flow
In the last 12 months, operating cash flow was -$12.85M and capital expenditures -$3, giving a free cash flow of -$12.85M.
| Operating Cash Flow | -12.85M |
| Capital Expenditures | -3 |
| Free Cash Flow | -12.85M |
| FCF Per Share | -3.93 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
SLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0% |
| FCF Yield | -602.28% |
Analyst Forecast
Currently there are no analyst rating for SLRX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jun 17, 2024. It was a backward split with a ratio of 1:8.
| Last Split Date | Jun 17, 2024 |
| Split Type | backward |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | -31.28 |
| Piotroski F-Score | 3 |